文献速递小儿眼科与斜弱视

绝经期激素治疗与斜视、斜视手术及再手术率的关系

Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates.
PubMed 文献 · Am J Ophthalmol · 2026-07-02

本研究基于Epic Cosmos数据库的回顾性临床队列,纳入2010年至2025年间44至60岁首次诊断绝经的女性患者。结果显示,绝经期激素治疗(MHT)与斜视诊断风险(HR 1.11)和斜视手术风险(HR 1.76)升高相关,但与再手术无显著关联。

要点

  • MHT使用与斜视诊断风险轻度升高相关(HR 1.11)。
  • MHT使用与斜视手术风险显著升高相关(HR 1.76)。
  • MHT与斜视再手术风险无显著关联。

核心结论

  • 在绝经女性中,MHT使用与斜视诊断和斜视手术风险增加相关,提示MHT可能与眼位结局存在潜在关系。

研究设计与样本

  • 回顾性临床队列研究,纳入Epic Cosmos中2010年1月1日至2025年10月31日期间44至60岁首次诊断绝经的女性患者。
  • MHT暴露定义为绝经诊断后使用雌激素或雌孕激素联合治疗≥90天,排除既往MHT使用者。
  • 采用时变Cox比例风险模型评估关联,调整年龄、绝经诊断年份、种族和民族。

主要发现

  • 共纳入2,154,255例绝经患者,其中197,576例(9.2%)接受MHT,1,956,679例(90.8%)未接受。
  • 绝经诊断平均年龄为54.9(4.1)岁,67.3%自我认同为白人。
  • MHT使用与斜视诊断风险升高相关(HR 1.11,95% CI 1.02-1.22;P = 0.015)。
  • MHT使用与斜视手术风险升高相关(HR 1.76,95% CI 1.38-2.25;P < 0.001)。
  • MHT使用与再手术风险无显著关联。

临床怎么用

  • 在评估绝经女性斜视风险时,可将MHT使用史作为参考因素之一。
  • 对于接受MHT的绝经女性,若出现眼位异常,应考虑斜视诊断和手术风险可能升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association between menopausal hormone therapy (MHT) and strabismus outcomes in menopausal women. DESIGN: Retrospective clinical cohort study. PARTICIPANTS: Female patients in Epic Cosmos with a first menopause diagnosis between ages 44 and 60 years from January 1, 2010, to October 31, 2025 were included. MHT exposure was defined as estrogen or combined estrogen-progestin use for ≥90 days after menopause diagnosis; patients with prior MHT use were excluded. METHODS: Demographic, clinical, and MHT data were extracted. Associations between MHT and strabismus diagnosis, surgery, and reoperation were assessed using time-varying Cox proportional hazards models adjusted for age and year of menopause diagnosis, race, and ethnicity. MAIN OUTCOME MEASURES: Strabismus diagnosis, strabismus surgery, and reoperation, excluding congenital, mechanical, neurological, paralytic, and traumatic causes. RESULTS: Among 2,154,255 menopausal patients, 197,576 (9.2%) received MHT and 1,956,679 (90.8%) did not. Mean age at menopause diagnosis was 54.9 (4.1) years, and 67.3% identified as White. MHT use was associated with higher hazards of strabismus diagnosis (HR 1.11, 95% CI 1.02-1.22; P = 0.015) and strabismus surgery (HR 1.76, 95% CI 1.38-2.25; P < 0.001), but not reoperation. CONCLUSION: MHT was associated with increased risk of strabismus diagnosis and surgery in menopausal women, suggesting a potential relationship between MHT and ocular alignment outcomes.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Legala AR, Nishida T, Liang A, et al. Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates. Am J Ophthalmol. 2026. PMID: 42385926. doi:10.1016/j.ajo.2026.06.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。